Proactive Investors - Run By Investors For Investors

Zelda Therapeutics poised to 'value add all the way from clinical trials to the market'

Dr Richard Hopkins, the newly appointed managing director of Zelda Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF), talks Proactive Investors through the medical cannabis researcher's recent strategic review, and provides updates on the company's three current clinical trials.

In its efforts to commercialise by bringing products to global markets as rapidly as possible, Zelda will focus on downstream integration, in contrast with many peer companies that are integrating upstream into cannabis cultivation.

Clinical trials are still at the centre of Zelda's operations. Currently there are trials ongoing for: opioid reducing pain management with St Vincent’s Hospital in Melbourne; insomnia with one of Australia’s leading sleep research centres; and paediatric patients with autism at the Children's Hospital of Philadelphia in the US.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here  
View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use